AeroLeads people directory · profile
Laura Sepp-Lorenzino, Ph.D. Email & Phone Number
At-Large Director (2025-2028)
at
American Society of Gene & Cell Therapy
2 work emails found
@intelliatx.com
2 phones found area 267 and 617
LinkedIn matched
✓ Verified July 2026
4 data sources
Profile completeness 100%
Current company
Role
At-Large Director (2025-2028)
Location
Boston, Massachusetts, United States
Who is Laura Sepp-Lorenzino, Ph.D.? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Laura Sepp-Lorenzino, Ph.D. is listed as At-Large Director (2025-2028) at American Society of Gene & Cell Therapy, based in Boston, Massachusetts, United States. AeroLeads shows a work email signal at intelliatx.com, phone signal with area code 267, 617, and a matched LinkedIn profile for Laura Sepp-Lorenzino, Ph.D..
Laura Sepp-Lorenzino, Ph.D. previously worked as Chief Scientific Officer at Intellia Therapeutics, Inc. and Member, Scientific Advisory Board at Thermo Fisher Scientific. Laura Sepp-Lorenzino, Ph.D. holds Ph.D., Biochemistry from New York University.
Company email context
Email format at American Society of Gene & Cell Therapy
This section adds company-level context without repeating Laura Sepp-Lorenzino, Ph.D.'s masked contact details.
*@intelliatx.com
71% confidence
AeroLeads found 2 current-domain work email signals for Laura Sepp-Lorenzino, Ph.D.. Compare company email patterns before reaching out.
Profile bio
About Laura Sepp-Lorenzino, Ph.D.
Innovative leader in drug discovery and development of small molecule and oligonucleotide therapeutics, with over 20 years of experience in academic and industrial settings. Defines and implements internal and external research strategy, incorporating disruptive, enabling technologies.Builds responsive, collaborative teams across geographies and functions.Nurtures a learning environment across the organization; coaching, mentoring.Optimizes operations and cost structures, delivering on objectives.Builds value via in- and out- licensing opportunities, partnerships, and new company development.
Listed skills include Drug Discovery, Biotechnology, Biomarkers, Biochemistry, and 27 others.
Current workplace
Laura Sepp-Lorenzino, Ph.D.'s current company
Company context helps verify the profile and gives searchers a useful next step.
American Society Of Gene & Cell Therapy
AeroLeads page
12 roles
Laura Sepp-Lorenzino, Ph.D. work experience
A career timeline built from the work history available for this profile.
Chief Scientific Officer
Current
May 2019 - Present
Member, Scientific Advisory Board
Current
Oct 2018 - Present
Vice President, Head Nucleic Acid Therapies, External Innovation
Sep 2017 - May 2019
Consultant
Jul 2015 - Sep 2017
Vice President, Entrepreneur In Residence
Built and led Hepatic Infectious Disease Strategic Therapeutic AreaResponsible for strategy and execution of infectious disease RNAi drug pipeline, which including programs for chronic hepatitis B and Dhttp://www.alnylam.com/product-pipeline/hepatic-infectious-disease/siRNA platform optimization and new target discovery and validationBusiness development, licensing and strategic collaborations. Strategic partnership with Vir Biotechnology, Inc.
Apr 2014 - Sep 2017
Executive Director / Senior Director, Rna Therapeutics Discovery Biology, Department Head
Responsible for biology strategy and activities towards identification/optimization of siRNAs and delivery vehicles, advancement of siRNA candidates, and utilization of siRNA tools for in vitro and in vivo target/biomarker validation and de-risking across functions and disease areas.Consolidated operations from Sirna San Francisco into single integrated Biology department at PA site (site closure, asset, personnel and technology transfer). Member of RNA Therapeutics Core Leadership Team, West Point Site Core Leadership Team, and RNA Review and Licensing Committee.
Aug 2011 - Mar 2014
Senior Director, Rna Therapeutics Delivery Biology, Department Head
As member of the RNA Therapeutics Leadership team, designed, enabled and implemented area strategy, working effectively across organizational and geographic boundaries.Led department responsible for identification and development of safe and efficacious oligonucleotide delivery formulations. Oversaw project teams for three oligonucleotide delivery modalities: lipid nanoparticles (LNP), polymer conjugates and siRNA conjugates, as well as exploratory targeted delivery efforts. Led an innovative team of biochemists and pharmacologists employing cutting-edge biochemical, cell and in vivo technologies to advance mechanistic understanding of oligonucleotide delivery at the organismal, cellular and subcellular levels. Carried out investigative toxicology studies on delivery formulations and established predictive assays and protocols that enabled >100-fold widening of safety margins. Identified Lipid Nanoparticle formulations with potency and safety profile compatible with clinical development. Advanced siRNA therapeutic programs through internal R+D stage gates in collaboration with disease areas and development functions. Contributed to regulatory documents.Evaluated over 500 licensing opportunities; established numerous collaborations and partnerships to advance internal capabilities.
Jan 2007 - Aug 2011
Director, Vaccines And Biologics Research
Pioneered the use of siRNA technology for in vivo studies and therapeutic applications.Played a significant role in establishing a strategic partnership with Alnylam Therapeutics and in the acquisition of Sirna Therapeutics.Member of Vaccines and Biologics Leadership Team, and Technology Review and Licensing Committee.
Jan 2006 - Jan 2007
Director / Senior Research Fellow, Cancer Research, Department Head
Responsible for cell cycle, checkpoint and cell survival Oncology target pipeline. Advanced three small molecule programs, from target validation through clinical development (Phase I/II). Member of Site Leadership Team, Franchise Operating Committee and Oncology Review and Licensing Committee. Participated in establishing and executing on licensing strategy; performed multiple licensing evaluations and due-diligence; in-licensed Vertex VX-680 (member of Joint Steering Committee) and Pierre Fabre IGF-I receptor monoclonal antibody.Evaluated and implemented enabling technologies: established high-throughput, high-content imaging facility, and performed tumor responder and drug combination in vitro assays for established and pipeline drugs. Partnered with Biologics Research to identify tumor antigens for targeted delivery.
Nov 2003 - Dec 2005
Research Fellow And Project Team Lead, Cancer Research
Led interdisciplinary team for small molecule tyrosine kinase inhibitor of KDR and Flt-3. Successfully advanced program through all drug discovery and development stages, from target validation, lead optimization, biomarker development, in vivo pharmacology. Authored biology section of IND; supported phase I trials by developing and performing bone marrow target engagement biomarker assays. Designed new tools and protocols for anti-angiogenesis drug discovery, including development, validation and qualification of patient enrichment and response biomarkers. First Oncology program at Merck to incorporate patient expression profiling – early adopter of new technology (Rosetta Inpharmatics) - and dynamic contrast enhanced MRI.
Dec 1999 - Oct 2003
Assistant Lab Member, Assistant Attending Molecular Biologist
Translational cancer programs and research collaborations with several pharmaceutical companies. Investigated mechanism of action of inhibitors of Hsp90, farnesyl transferases, receptor and cytoplasmic tyrosine kinase, and of several fully synthetic natural products in collaboration with Professors Neal Rosen and Sam Danishefsky. Contributed to advancing 17-allyl-amino-geldanamycin Hsp90 inhibitor program to the clinic and contributed to the identification and characterization of next generation Hsp90 inhibitors. Explored targeted delivery of Hsp90 inhibitors to prostate cancer using small molecule and monoclonal antibody conjugates.
Jan 1995 - Dec 1999
2 education records
Laura Sepp-Lorenzino, Ph.D. education
Ph.D., Biochemistry
New York University
Biochemist (Professional 6 Yr Degree), Pharmacy & Biochemistry
University Of Buenos Aires
FAQ
Frequently asked questions about Laura Sepp-Lorenzino, Ph.D.
Quick answers generated from the profile data available on this page.
What company does Laura Sepp-Lorenzino, Ph.D. work for?
Laura Sepp-Lorenzino, Ph.D. works for American Society of Gene & Cell Therapy.
What is Laura Sepp-Lorenzino, Ph.D.'s role at American Society of Gene & Cell Therapy?
Laura Sepp-Lorenzino, Ph.D. is listed as At-Large Director (2025-2028) at American Society of Gene & Cell Therapy.
What is Laura Sepp-Lorenzino, Ph.D.'s email address?
AeroLeads has found 2 work email signals at @intelliatx.com for Laura Sepp-Lorenzino, Ph.D. at American Society of Gene & Cell Therapy.
What is Laura Sepp-Lorenzino, Ph.D.'s phone number?
AeroLeads has found 2 phone signal(s) with area code 267, 617 for Laura Sepp-Lorenzino, Ph.D. at American Society of Gene & Cell Therapy.
Where is Laura Sepp-Lorenzino, Ph.D. based?
Laura Sepp-Lorenzino, Ph.D. is based in Boston, Massachusetts, United States while working with American Society of Gene & Cell Therapy.
What companies has Laura Sepp-Lorenzino, Ph.D. worked for?
Laura Sepp-Lorenzino, Ph.D. has worked for American Society Of Gene & Cell Therapy, Intellia Therapeutics, Inc., Thermo Fisher Scientific, Vertex Pharmaceuticals, and Third Rock Ventures.
How can I contact Laura Sepp-Lorenzino, Ph.D.?
You can use AeroLeads to view verified contact signals for Laura Sepp-Lorenzino, Ph.D. at American Society of Gene & Cell Therapy, including work email, phone, and LinkedIn data when available.
What schools did Laura Sepp-Lorenzino, Ph.D. attend?
Laura Sepp-Lorenzino, Ph.D. holds Ph.D., Biochemistry from New York University.
What skills is Laura Sepp-Lorenzino, Ph.D. known for?
Laura Sepp-Lorenzino, Ph.D. is listed with skills including Drug Discovery, Biotechnology, Biomarkers, Biochemistry, Clinical Development, Lifesciences, Pharmacology, and Life Sciences.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial